Is Tscan Therapeutics Inc (TCRX) overvalued? · rev $2.0M
Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ.
This page asks whether Tscan Therapeutics Inc (TCRX) looks expensive on cached numbers — not a short thesis.
Latest reported TCRX revenue for 2026-06-30 was $2.0M. Net income was -$59.0M. TCRX currently screens at market cap $62.1M.
TCRX currently screens at market cap $62.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TCRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TCRX stock page for the full model, not this heading.
Not investment advice.